Biotechnology stocks can be thrilling and profitable when you’re on the winning side of a trade. G1 Therapeutics’ (NASDAQ:GTHX) started hot, but then the bottom fell out after an unfortunate announcement. With that in mind, G1 Therapeutics stock is just too risky to recommend right now.Based in North Carolina, G1 Therapeutics specializes in oncology (cancer) treatments. To be fair and balanced, I’ll start off with some positive news pertaining to G1 Therapeutics. Then, however, I’ll have to release a bombsh ...